Hemp Headlines & High Hopes: This Week in Cannabis
No se pudo agregar al carrito
Add to Cart failed.
Error al Agregar a Lista de Deseos.
Error al eliminar de la lista de deseos.
Error al añadir a tu biblioteca
Error al seguir el podcast
Error al dejar de seguir el podcast
-
Narrado por:
-
De:
In this episode of Let’s Be Blunt with Montel, we’re diving into the latest cannabis and hemp news that’s making waves across the industry. From the controversial new federal hemp regulations that could reshape the market to groundbreaking health studies showing the cognitive benefits of cannabis use in older adults, we’ve got it all covered.
We’ll also explore the Trump administration’s potential move to reclassify marijuana as a Schedule III drug, the Supreme Court case that could set a precedent for CBD product labeling, and the ongoing battle over hemp-THC regulations in states like Ohio, Missouri, and Minnesota. Plus, we’ll break down the latest business updates, including major moves from companies like Trulieve, Curaleaf, and Canopy Growth.
On a personal note, Montel shares how the latest health research hits close to home, as it highlights the long-term cognitive benefits of cannabis use—something he’s experienced firsthand over the past 25 years.
Finally, we want to hear from YOU! Share your thoughts on the new hemp regulations, state-level legalization efforts, or your own cannabis journey. Your feedback could be featured in a future episode.
Tune in for an informative, engaging, and empowering discussion that keeps you in the know about all things cannabis.
Key Topics Covered:
- Federal hemp regulations and their potential impact
- Health studies on cannabis and cognitive performance in older adults
- State-level legalization updates in Virginia, Ohio, and Minnesota
- Business highlights from Trulieve, Curaleaf, and more
- The Supreme Court case on CBD product labeling
Stay informed, stay empowered, and stay blunt!
Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.